Olga Znoyko
Moscow, MOW, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy
Journal: Terapevticheskii arkhiv
Published: October 10, 2023
Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C
Journal: Terapevticheskii arkhiv
Published: April 16, 2020
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Journal: European journal of gastroenterology & hepatology
Published: May 16, 2018
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Published: June 22, 2016
Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2
Journal: Terapevticheskii arkhiv
Published: May 31, 2016
Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice
Journal: Terapevticheskii arkhiv
Published: January 01, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026